Translational cancer research最新文献

{"title":"Efficacy of transcatheter arterial chemoembolization-based multimodal treatment in patients with neuroendocrine tumors involving the liver.","authors":"Hu Xu, Li Zhang, Juan Zhang, Yi Chen, Ningling Ge, Yuhong Gan, Rongxin Chen, Maopei Chen","doi":"10.21037/tcr-2024-2482","DOIUrl":"10.21037/tcr-2024-2482","url":null,"abstract":"<p><strong>Background: </strong>Neuroendocrine tumors (NETs) are a group of heterogeneous diseases which have liver dominant involvement potency. The value of transcatheter arterial chemoembolization (TACE) treatment for NET patients in the era of somatostatin analogues (SSAs) and anti-proliferation agents needs further study. The study aimed to investigate the value of TACE-based treatment for NETs involving the liver.</p><p><strong>Methods: </strong>A group of 29 NET patients received TACE-based multimodal treatment in the Department of Hepatic Oncology of Zhongshan Hospital, Fudan University was retrospectively collected. Baseline characteristics of included patients were analyzed. Kaplan-Meier analysis and Cox proportional hazards regression were used to investigate clinical and pathological parameters on overall survival (OS) and progression free-survival (PFS) in NET patients.</p><p><strong>Results: </strong>The median OS and PFS were 20.0 [95% confidence interval (CI): 13.4-26.5] months and 11.0 (95% CI: 7.7-14.3) months, respectively. Tumor grade (P=0.001), number of TACE treatments (P=0.003), neutrophil to lymphocyte ratio (NLR) (P=0.005) and systemic treatment mode (P=0.007) were significantly associated with OS while tumor grade (P<0.001), number of TACE treatments (P=0.002), aspartate aminotransferase (AST) (P=0.01) and systemic treatment mode (P=0.001) were of significance to PFS in multivariate Cox regression analyses.</p><p><strong>Conclusions: </strong>TACE-based multimodal treatment is beneficial for NETs involving the liver. The sequence and timing of local treatment and systemic treatment allocation need further investigation.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4321-4330"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn.","authors":"Dena Hasan, J Chad Brenner, Paul L Swiecicki, Molly E Heft Neal","doi":"10.21037/tcr-2025-782","DOIUrl":"10.21037/tcr-2025-782","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"3887-3891"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line treatment of extensive-stage small cell lung cancer with immune checkpoint inhibitors acting on different targets: a systematic review and network meta-analysis.","authors":"Meng Li, Yu-Zhu Chen, Da-Zhong Chen, Yang Wang, Hong-Li Zhao","doi":"10.21037/tcr-2025-430","DOIUrl":"10.21037/tcr-2025-430","url":null,"abstract":"<p><strong>Background: </strong>Incorporating immune checkpoint inhibitors (ICIs) into the platinum and etoposide regimen for extensive-stage small-cell lung cancer (ES-SCLC) has been established as the standard of care for first-line treatment. Currently, there is still no network meta-analysis (NMA) to evaluate the differences in efficacy and safety between ICIs targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death-ligand 1 (PD-L1). This Bayesian NMA aims to evaluate the differences in efficacy and safety among ICIs targeting CTLA-4, PD-1, and PD-L1 as first-line treatments for ES-SCLC. By providing an evidence-based framework, we seek to address existing clinical research gaps and guide the selection of optimal ICIs for future trials.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Cochrane Library, and Web of Science to retrieve relevant randomized, controlled clinical trials (RCTs) published up to 16 February 2025. The key inclusion criteria are (I) histologically or cytologically confirmed ES-SCLC; (II) platinum-containing two-agent chemotherapy combined with only one ICI as first-line treatment for ES-SCLC; (III) phase II or III RCTs with results reporting hazard ratios (HR) and confidence intervals (CI) of at least one of progression-free survival (PFS) or overall survival (OS). The Markov Chain Monte Carlo method, implemented within the GEMTC and the JAGS package in R software, was used to conduct this NMA. Risk of bias assessment, heterogeneity testing, model reliability assessment, and sensitivity analyses were performed to ensure the robustness of the results.</p><p><strong>Results: </strong>Fifteen publications and 5,761 patients included in the final NMA are attributed to 13 clinical trials, of which 10 are phase III clinical trials, 3 are phase II clinical trials, 2 are clinical trials for CTLA-4 targets, 4 are clinical trials for PD-L1 targets, and 7 are clinical trials for PD-1 targets. Both the fixed effect modeling of the main and sensitivity analyses showed that CTLA-4 inhibitors (CTLA-4i) increased the risk of death compared with PD-1 inhibitors (PD-1i) [HR, 1.25 (95% CI: 1.06, 1.46)] and PD-L1 inhibitors (PD-L1i) [HR, 1.24 (95% CI: 1.05, 1.47)]. For PFS, objective response rate (ORR), and grade 3 or higher adverse events (≥grade 3 AEs), the main analyses and sensitivity analyses showed that no difference among CTLA-4i, PD-1i, and PD-L1i.</p><p><strong>Conclusions: </strong>CTLA-4i in combination with etoposide and platinum increased the risk of death compared to PD-1i/PD-L1i in combination with etoposide and platinum, which may be related to the timing of CTLA-4i application.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"3961-3972"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification and influencing factors of family resilience and posttraumatic growth in patients with spinal tumor: a cross-sectional study.","authors":"Di Hu, Qian Ma, Lifeng Yao, Xiaoju Zhang, Lijuan Xu, Li Chen","doi":"10.21037/tcr-2025-1271","DOIUrl":"10.21037/tcr-2025-1271","url":null,"abstract":"<p><strong>Background: </strong>Spinal tumors severely impact patients' quality of life and place a heavy psychological and emotional burden on families. Characterizing the patterns of posttraumatic growth (PTG) and family resilience is essential for developing targeted support interventions. However, existing research has primarily focused on patients' physical and psychological symptoms, with limited attention given to how families adapt and grow in the face of spinal tumors. Moreover, few studies have explored the typologies or underlying determinants of family resilience and PTG in this population. The aim of this study was to investigate the possible classifications and determinants of family resilience and PTG among individuals with spinal tumors.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey of 219 patients with malignant spinal tumors treated at the Fudan University Shanghai Cancer Center from July 2021 to July 2022. Eligible participants were aged 18 years or older, diagnosed with primary or secondary spinal tumors, and capable of completing the questionnaires in Chinese. Participants completed self-administered questionnaires with optional assistance from trained investigators, including the General Demographic Information Form, Chinese-Family Resilience Assessment Scale (FRAS-C), Posttraumatic Growth Inventory (PTGI), Family Crisis-Oriented Personal Evaluation Scales (FCOPES), and Social Support Rating Scale (SSRS). Latent profile analysis (LPA) was used to identify subgroups based on the FRAS-C and PTGI dimensions, followed by chi-square tests and multinomial logistic regression to explore differences and influencing factors.</p><p><strong>Results: </strong>Among the 219 patients, 28.3% had primary spinal tumors, and 71.7% had secondary spinal tumors. The sample had a mean age of 55.7 (standard deviation =14.8; range, 18-84) years, with 52.5% male, and included 62 patients with primary tumors and 157 with secondary tumors. LPA categorized respondents into three groups: resistance-in-adversity (17.4%), struggling-resilience-group (45.2%), and adaptive growth group (37.4%). Significant differences were observed between these groups in terms of occupational status, housework commitment, family atmosphere, and scores on the FCOPES and SSRS scales. Regression analyses indicated that retirement [odds ratio (OR) =2.928; 95% confidence interval (CI): 1.098-7.808], family coping (OR =1.113; 95% CI: 1.063-1.165), and social support (OR =1.226; 95% CI: 1.103-1.362) were significantly associated with family resilience and PTG (P<0.05).</p><p><strong>Conclusions: </strong>Patients with spinal tumors demonstrate distinct profiles of family resilience and PTG. Factors such as coping ability and social support play key roles in determining patient classification. These findings highlight the importance of stratified psychosocial interventions tailored to different patient subgroups to promote adaptive recovery and family adjus","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4447-4460"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating single-cell and bulk RNA sequencing data to construct a pyroptosis-related prognostic signature and analyze the tumor microenvironment in gastric cancer.","authors":"Ruiyu Wang, Shu Huang, Ping Wang, Rui Luo, Yizhou Wang, Xiaomin Shi, Wei Zhang, Lei Shi, Xian Zhou, Xiaowei Tang","doi":"10.21037/tcr-2024-2660","DOIUrl":"10.21037/tcr-2024-2660","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a prevalent malignancy with high morbidity and mortality. Pyroptosis, a form of programmed cell death, plays a significant role in cancer progression and immune regulation. This study aimed to construct a pyroptosis-related prognostic signature (PRPS) and analyze its association with the tumor microenvironment in GC by integrating single-cell and bulk RNA sequencing data.</p><p><strong>Methods: </strong>Pyroptosis-related differentially expressed genes in GC were identified by integrating single-cell and bulk RNA sequencing data. The PRPS was constructed using univariate and multivariate Cox regression analyses, and evaluated by Kaplan-Meier curves, receiver operating characteristic curves, and nomogram analysis. Subsequently, genomic variations, immune landscapes, immune checkpoint inhibitors (ICIs) responses, and drug sensitivity were evaluated in different risk subgroups.</p><p><strong>Results: </strong>We constructed a PRPS in GC by integrating single-cell and bulk RNA sequencing data. The PRPS exhibited strong predictive efficiency, with the high-risk group showing significantly lower overall survival, progression-free survival, and disease-specific survival. Multivariate Cox regression validated the PRPS as an independent prognostic factor, while the PRPS-based nomogram showed high predictive accuracy. Functional enrichment and immune landscape analysis revealed the differences between the risk subgroups in immune pathways, gene mutations, immune cell infiltration, and tumor mutational burden. Analysis of ICIs responses and drug sensitivity showed the differences in treatment among different risk subgroups, providing a basis for personalized treatment.</p><p><strong>Conclusions: </strong>The PRPS provides a promising tool for the prognostic prediction, targeted prevention, and personalized treatment for GC, and may promote the precision medicine for GC patients.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4080-4099"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of <i>ANKRD22</i> and its prognostic significance in squamous cell carcinoma of the cervix: a bioinformatics analysis based on public datasets.","authors":"Hyung-Joon Yoon, Eun Taeg Kim, Changho Song","doi":"10.21037/tcr-2025-307","DOIUrl":"10.21037/tcr-2025-307","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer (CC) is the fourth most common cancer in women. Prognostic biomarkers for CC, particularly squamous cell carcinoma (SCC), are limited despite their clinical significance. ANKRD22, an ankyrin repeat domain protein, has been implicated in several cancers, but its role in CC remains unclear. In this study, we aimed to analyze the relationship between <i>ANKRD22</i> expression and the prognosis of patients with CC, especially SCC.</p><p><strong>Methods: </strong>Gene expression profiles were obtained from GEO datasets (GSE63514, GSE6791), and RNA sequencing and clinical data were obtained from The Cancer Genome Atlas. Clinical characteristics included age, Federation of Gynecology and Obstetrics 2009 stage, histological grade, lympho-vascular space invasion, and treatment response. Patients were stratified by <i>ANKRD22</i> expression, and survival analyses were conducted using Kaplan-Meier and Cox regression models.</p><p><strong>Results: </strong><i>ANKRD22</i> expression was significantly lower in CC tissues than in normal tissues. In SCC patients, the lower <i>ANKRD22</i> expression was associated with worse overall survival (OS) [P=0.008, hazard ratio (HR) =0.494, 95% confidence interval (CI): 0.290-0.840] and progression-free survival (PFS) (P=0.01, HR =0.510, 95% CI: 0.295-0.880). Multivariate Cox regression analysis identified <i>ANKRD22</i> downregulation as an independent prognostic factor. Lower expression was also correlated with higher histological grade.</p><p><strong>Conclusions: </strong><i>ANKRD22</i> downregulation is associated with poor prognosis in SCC of the cervix. While these findings suggest prognostic relevance, further experimental studies are necessary to validate <i>ANKRD22</i>'s clinical utility.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4034-4045"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family resilience and related influencing factors in Chinese patients with malignant spinal tumors: a cross-sectional study.","authors":"Liuqing Cao, Leiting Gu, Lijuan Xu, Lifeng Yao, Daniele Vanni, Zhenqi Lu, Li Chen, Xiaoju Zhang","doi":"10.21037/tcr-2025-1033","DOIUrl":"10.21037/tcr-2025-1033","url":null,"abstract":"<p><strong>Background: </strong>Malignant spinal tumors often disrupt family dynamics, posing significant psychological and caregiving challenges. Family resilience-the ability to adapt and maintain functioning during adversity-is essential, yet understudied in this population. This study aimed to assess the level of family resilience and its associated factors among patients with malignant spinal tumors.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from July 2021 to July 2022 at two wards of Fudan University Shanghai Cancer Center. A total of 219 patients with confirmed malignant spinal tumors were recruited through convenience sampling based on specific inclusion and exclusion criteria. Data were collected using standardized instruments, including the Chinese version of the Family Resilience Assessment Scale (FRAS-C), Family Care Index Scale (APGAR), and the Social Support Rating Scale (SSRS). A pilot study validated the reliability of instruments prior to data collection. Demographic and clinical data, including neurological function and self-care ability, were also recorded. Pearson correlation, univariate analysis, and multiple linear regression were performed to identify factors associated with family resilience.</p><p><strong>Results: </strong>Among 232 distributed questionnaires, 219 valid responses were collected (response rate: 94.4%). Of the participants, 62 had primary spinal tumors and 157 had metastatic tumors. The mean age was 56 (standard deviation =15; range, 18-84) years, and 41.6% exhibited neurological dysfunction. Additionally, 47.9% showed reduced self-care ability. The FRAS-C score of 219 patients with malignant spinal tumors was (93.79±10.36) points, among which the score of social resource utilization dimension was the lowest (8.08±1.70) points. The score of APGAR was (7.58±2.09) points, but there were still 27.9% patients with moderate to severe family dysfunction, among which the scores of growth and cooperation dimensions were the lowest which were (1.47±0.56) points and (1.48±0.58) points, respectively. The score of SSRS was (39.45±5.36) points, which was at a moderate level. Univariate analysis showed that the level of family resilience of divorced widows was significantly lower than that of married and unmarried patients. The level of resilience of single-parent families is lower than that of nuclear families and main families; The warmer the patient's home atmosphere, the higher the family resilience level. Patients with paraplegia had lower levels of family stress resistance than those with normal neurological function. Findings confirm family resilience correlates positively with family function (r=0.46, P<0.05) and social support (r=0.30, P<0.05).</p><p><strong>Conclusions: </strong>Family resilience among patients with malignant spinal tumors was moderate, with particular deficiencies in social resource utilization. Findings underscore the importance of incorporating family-centered car","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4416-4428"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicotine-induced PD-L1 expression in lung squamous cell carcinoma is mediated by the α7-nAChR/STAT3 signaling pathway.","authors":"Yinan Li, Wenting Wang, Yaoyao Wang, Ce Zhou, Xin Zou, Yixuan Wang, Ning Wang","doi":"10.21037/tcr-2024-2587","DOIUrl":"10.21037/tcr-2024-2587","url":null,"abstract":"<p><strong>Background: </strong>Nicotine, the principal addictive component of tobacco smoke, promotes lung cancer cell proliferation via α7 nicotinic acetylcholine receptors (α7-nAChRs). Programmed death-ligand 1 (PD-L1) serves as a crucial predictive biomarker for immune checkpoint inhibitor (ICI) therapy in lung squamous cell carcinoma (LUSC). This study aimed to investigate the expression patterns of α7-nAChR and its encoding gene <i>CHRNA7</i> in LUSC tissues, and to evaluate their associations with PD-L1 expression.</p><p><strong>Methods: </strong><i>CHRNA7</i> expression, its correlation with clinicopathological features, and survival outcomes in LUSC were analyzed using The Cancer Genome Atlas (TCGA) database and Kaplan-Meier plotter. The expression levels of α7-nAChR and PD-L1 in LUSC tissues and cell lines were evaluated by immunohistochemistry and Western blot (WB). Following nicotine stimulation and small interfering RNA (siRNA) transfection, messenger RNA (mRNA) expression levels of <i>CHRNA7</i>, signal transducer and activator of transcription 3 (STAT3), and CD274 (PD-L1) were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), while their protein levels were assessed by WB.</p><p><strong>Results: </strong><i>CHRNA7</i> expression was significantly elevated in LUSC tissues and cell lines compared to adjacent normal tissues and bronchial epithelial cell lines (P<0.05), and correlated with smoking status. Higher <i>CHRNA7</i> expression was associated with shorter overall survival. Nicotine stimulation (1.0 μM) significantly increased the mRNA expression levels of <i>CHRNA7</i>, STAT3, and CD274 in LUSC cell lines. Knockdown of siRNA-mediated <i>CHRNA7</i> in LUSC cell lines decreased STAT3 phosphorylation (pSTAT3) and PD-L1 protein levels, while attenuating nicotine-induced PD-L1 upregulation. STAT3 silencing had no significant effect on α7-nAChR protein expression but downregulated PD-L1 protein levels and attenuated nicotine-induced PD-L1 upregulation.</p><p><strong>Conclusions: </strong>α7-nAChR and its encoding gene <i>CHRNA7</i> are upregulated in LUSC tissue and are associated with smoking status. Patients with high expression of <i>CHRNA7</i> have a relatively worse prognosis. Nicotine may upregulate PD-L1 expression in LUSC through the α7-nAChR/STAT3 pathway.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4293-4304"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic implications of store-operated calcium entry signatures and immune dynamics in neuroblastoma via machine learning.","authors":"Wanrong Li, Xin Li, Jian Wang","doi":"10.21037/tcr-2024-2563","DOIUrl":"10.21037/tcr-2024-2563","url":null,"abstract":"<p><strong>Background: </strong>Neuroblastoma is a highly heterogeneous pediatric malignancy, with high-risk cases exhibiting poor clinical outcomes. Store-operated calcium entry (SOCE) channels have been implicated in cancer progression, yet their prognostic significance in neuroblastoma remains unclear. This study aimed to investigate the relevance of SOCE-related genes in predicting patient prognosis and guiding therapeutic strategies.</p><p><strong>Methods: </strong>We performed unsupervised clustering based on SOCE-related gene expression in multiple neuroblastoma RNA sequencing (RNA-seq) datasets. A prognostic scoring system, the SOCE_Score, was developed using machine learning algorithms. The model's predictive performance was validated across independent datasets. Immune characteristics were assessed using established deconvolution algorithms, and candidate therapeutic compounds were identified via the Connectivity Map (CMap) platform.</p><p><strong>Results: </strong>Two distinct molecular clusters were identified, differing significantly in survival outcomes, immune infiltration, and stemness signatures. The SOCE_Score stratified patients with high accuracy and outperformed conventional clinical predictors. Lower SOCE_Score groups were associated with favorable immune landscapes and greater responsiveness to immune checkpoint blockade. CMap analysis highlighted MS-275, a histone deacetylase (HDAC) inhibitor, as a promising compound targeting low SOCE_Score phenotypes.</p><p><strong>Conclusions: </strong>SOCE-related transcriptional features serve as robust biomarkers for prognosis and immune activity in neuroblastoma. The SOCE_Score holds potential for guiding risk stratification, immunotherapeutic selection, and drug repurposing efforts. These findings underscore the clinical utility of integrating calcium signaling profiles into neuroblastoma management and warrant further experimental validation.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4179-4193"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between the decreased expression of NUDT18 and tumor progression in endometrial cancer.","authors":"Yue Hua, Mengdan Miao, Yan Wang, Huaijun Zhou","doi":"10.21037/tcr-2024-2538","DOIUrl":"10.21037/tcr-2024-2538","url":null,"abstract":"<p><strong>Background: </strong>Nudix hydrolase 18 (NUDT18) belongs to the family of nudix hydrolases. This study aimed to clarify the relationship between NUDT18 and endometrial cancer (EC) and whether it is a prognostic factor for EC.</p><p><strong>Methods: </strong>We first examined the function of NUDT18 through The Cancer Genome Atlas public data and Human Protein Atlas databases, and then immunohistochemical staining was conducted to compare the expression of NUDT18 in normal endometrium and EC tissues of different stages. Finally, we performed gene set enrichment analysis (GSEA) to identify the signaling pathways regulated by NUDT18 in EC.</p><p><strong>Results: </strong>We found that NUDT18 expression was considerably elevated in EC tissues relative to physiological endometrium (P<0.001). However, Kaplan-Meier analysis revealed that high NUDT18 expression in EC was associated with a longer overall survival (OS). Immunohistochemistry results showed that NUDT18 expression was upregulated in tissues of early-stage EC compared with normal endometrial tissues and gradually decreased with the increase of stage. NUDT18 expression was significantly associated with Federation of Gynecology and Obstetrics stage, histologic grade, and myometrial invasion (all P values <0.05). GSEA revealed that the biological pathways that were differentially downregulated in the NUDT18-high expression phenotype were cell cycle, the TGF-β signaling pathway, RNA degradation, adherens junction, basal transcription factors, and DNA replication. In addition, NUDT18 DNA copy gain and the downregulation of miR-758-3p exhibited a correlation with the upregulation of NUDT18 in EC, and NUDT18 expression was significantly reduced in tumors with the TP53 mutation. The analysis of immune cell abundance indicated a substantial increase in immune infiltration in EC tissues with high NUDT18 expression.</p><p><strong>Conclusions: </strong>NUDT18 was upregulated in EC relative to normal endometrium, and its expression inversely correlated with tumor stage. Notably, higher NUDT18 expression predicted improved OS, highlighting its clinical significance as a marker of favorable prognosis in EC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4279-4292"},"PeriodicalIF":1.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}